Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Abbott Laboratories

Abbott's Q2 2024 Earnings: What to Expect

Abbott is poised to release its second-quarter results this month, and analysts are projecting a slight increase in profits.

Barchart

3 Healthcare Stocks Set to Benefit From Aging Population Trends

The healthcare industry is set to grow significantly due to technological advances, an aging population, and increasing demand for quality healthcare. To that end, it could be wise to buy fundamentally strong healthcare stocks like Abbott Laboratories (ABT), Stryker (SYK), and Centene (CNC), which are set to benefit from these…

StockNews.com

3 Top-Rated Dividend Kings Trading Near Their 52-Week Lows

These quality companies all have something in common: They are trading a little off their 52-week lows and pay an ever-increasing dividend.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Top S&P 500 Stocks With Strong Analyst Ratings

The S&P 500 index’s 2024 rally continued in June as solid corporate earnings outweighed concerns over slower economic growth and a potential delay in the Fed’s pivot to interest rate cuts. Further, several Wall Street strategists raised their year-end S&P 500 price targets. Hence, top-performing S&P 500 stocks Amazon.com (AMZN),…

StockNews.com

Abbott Snags U.S. Clearance To Enter The Obesity Arena, Rivaling Dexcom

Abbott Laboratories gained U.S. clearance Monday for a pair of new CGMs. But Abbott stock fell a fraction at the close.

Investors Business Daily

Volatility halts hit numerous NYSE-listed stocks in error

An apparent glitch at the operator of the New York Stock Exchange triggered volatility trading halts shortly after the open in about a dozen companies, including Chipotle Mexican Grill Inc. and Abbott Laboratories.

Evening Standard

Abbott Stock: Analyst Estimates & Ratings

Abbott has underperformed the broader market over the past year, but Wall Street analysts are optimistic about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

3 Near-oversold Dividend Aristocrats To Buy Before They Pop

These three Dividend Aristocrats trade near oversold levels and offer reliable income and potential capital appreciation.

Barchart

Medical device companies pay millions to NHS while pushing products, says study

Pharmaceutical equipment firms are funding NHS staff and training while promoting sales

The Guardian - UK

Abbott Exceeds Profit Expectations With Strong Medical Device Sales

Abbott Laboratories surpasses profit expectations with strong medical device sales, showcasing market leadership and growth strategies.

Top News

Abbott's 2024 Earnings Forecast Hits Below Estimates, Shares Decline

Abbott predicts lower-than-expected earnings for 2024, causing a decline in its shares. Investors are disappointed with the forecast.

StockNews.com

Analyzing 2024 Gain Potential in 3 Medical Stocks

The medical sector is poised for substantial gains this year, fueled by rising cases of chronic diseases and swift technological progress. In light of this, let’s analyze the fundamentals of three medical stocks: Abbott Laboratories (ABT), Agilent Technologies (A), and Viemed Healthcare (VMD). Read on….

Barchart

100 Years of Paying Dividends: Why You Need This Healthcare Stock

Dividend growth investors love this boring healthcare stock for three reasons: Growth, financial stability, and 100 years of paying dividends.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Stocks Close Lower on Heightened Geopolitical Risks and Soaring Bond Yields

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -1.34%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.98%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.41%. Stocks on Wednesday closed sharply lower, with the...

StockNews.com

Abbott Laboratories (ABT) Earnings Insights: Will the Medical Stock Build Investor Confidence?

Considering Abbott Laboratories' (ABT) recent strategic collaborations and acquisitions to boost the company’s long-term growth, could the stock be a compelling buy as we approach its fiscal third-quarter earnings release? Let's find out.

Investors Business Daily

Earn Extra Cash On ABT Stock Earnings, But Careful With This Risk

When volatility is high, it can be a good time to be an option seller rather than a buyer.

Barchart

Worried About a Recession? Protect Your Portfolio With These 3 Resilient Stocks

With geopolitical tensions rising, here are three stocks from different sectors that have the ability to weather this storm.

Barchart

Building Wealth with Spinoffs: How Adding These Gems Can Transform Your Portfolio

Spinoffs are value creating investment opportunities. You should be looking at them

Chicago Tribune

Abbott’s COVID-19 test sales dive by nearly 90%

Abbott Laboratories’ sales of COVID-19 tests fell by a whopping 89% during the second quarter of this year compared with the same time last year — a drop that comes as the world attempts to move on from the pandemic.

Tribune News Service

Humira, the world’s top-selling drug, faces an upcoming test from low cost alternatives

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.